HACOR in Action: Noninvasive Ventilation Failure in Acute Respiratory Failure

Ishikawa, O.; Ballenberger, Matthew; Birnbaum, Brian; Mina, Bushra; Esquinas, António M.; Gonçalves, Bruno Gil; Úbeda, Alejandro; Burgos, Irene Fernández; Fiorentino, Giuseppe; Lanza, Maurizia; Bozbay, Suha; Dikmen, Yalım; Duan, Jun

doi:10.1183/13993003.congress-2020.1961

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The patients received high-flow nasal oxygen (HFNO) using nasal cannula [ 29 ] or non-invasive ventilation with the continuous positive airway pressure (CPAP) variant, according to the Rox [ 30 ] index or the HACOR scale [ 31 ], respectively. In some cases, these oxygenation therapies were combined with awake prone positioning.…”

Section: Methodsmentioning

confidence: 99%

Jusvinza, an anti-inflammatory drug derived from the human heat-shock protein 60, for critically ill COVID-19 patients. An observational study

et al. 2023

View full text Add to dashboard Cite

This paper presents the results of an observational and retrospective study on the therapeutic effects of Jusvinza, an immunomodulatory peptide with anti-inflammatory properties for critically ill COVID-19 patients. This peptide induces regulatory mechanisms on the immune response in experimental systems and in patients with Rheumatoid Arthritis. Exploratory research in COVID-19 patients revealed that Jusvinza promotes clinical and radiological improvement. The aim of this study is to describe the clinical outcome and variations of several inflammatory biomarkers in a cohort of critically ill COVID-19 patients, divided into two groups during the observational research: one group received Jusvinza and the other did not. Research physicians extracted the patients´ data from their hospital’s clinical records. The study analyzed 345 medical records, and 249 records from critically ill patients were included. The data covered the demographic characteristics, vital signs, ventilatory parameters and inflammatory biomarkers. Survival outcome was significantly higher in the group receiving Jusvinza (90.4%) compared to the group without Jusvinza (39.5%). Furthermore, in patients treated with Jusvinza there was a significant improvement in ventilatory parameters and a reduction in inflammation and coagulation biomarkers. Our findings show that Jusvinza could control the extent of inflammation in COVID-19 patients. This study indicates that Jusvinza is a helpful drug for the treatment of diseases characterized by hyperinflammation.

show abstract

Section: Methodsmentioning

confidence: 99%